Iron deficiency anemia (IDA) continues to be a global public health problem. Oral iron is the universally accepted first-line therapy, and most children have a prompt and favorable response to oral formulations. In subsets of children who fail to respond due to intolerance, poor adherence, or inadequate intestinal absorption, parenteral iron is indicated. Despite numerous studies in adults with IDA of diverse etiologies, pediatric studies on parenteral iron use are very limited. Although mostly retrospective and small, these studies have documented the efficacy and safety profile of intravenous iron formulations. In this editorial the author comments on the most important published data and underscores the need to seriously consider parenteral iron use in children unresponsive to oral therapy.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11129126 | PMC |
http://dx.doi.org/10.12998/wjcc.v12.i13.2138 | DOI Listing |
Clin Nutr ESPEN
January 2025
Intestinal Failure Unit, Salford Royal NHS Foundation Trust, Salford M6 8HD, UK; School of Health Sciences, University of Manchester, Manchester M13 9PL, UK.
Background & Aims: Current estimates of the prevalence of iron deficiency anaemia (IDA) in patients with chronic intestinal failure (CIF) exceed those seen in general population, however, the studies to-date are limited with relatively small numbers of patients. The aim of the study was to determine the point prevalence of IDA in a large cohort of stable HPN-dependent adults managed by a specialist Intestinal Failure Unit.
Methods: This was a retrospective cohort study of HPN-dependent adults managed by a national UK IF Reference Centre between 01/01/2019 and 31/12/2019.
Curr Cardiol Rev
January 2025
Shri Venkateshwara University, Gajraula, Uttar Pradesh, India.
Iron deficiency anemia (IDA) is highly prevalent among individuals with heart failure (HF), impacting 40-70% of patients and serving as a significant prognostic indicator. Linked with oxidative metabolism and myocardial cell damage, IDA exacerbates HF symptoms, including reduced exercise capacity, diminished quality of life, and heightened cardiovascular morbidity. This review explores the diagnosis, treatment, clinical outcomes, prognostic indicators, and forthcoming challenges associated with IDA in HF patients.
View Article and Find Full Text PDFJ Family Med Prim Care
November 2024
Centre for Community Medicine, All India Institute of Medical Sciences, New Delhi, India.
Introduction: Intravenous iron sucrose (IVIS) is a rapidly acting, safe, and effective treatment for moderate anemia among pregnant women. The effectiveness of IVIS at 6 months post IVIS infusion was unknown. We, therefore, assessed the mean increase in hemoglobin concentration and body iron replenishment status at 6 months after the last dose of IVIS infusion.
View Article and Find Full Text PDFCureus
November 2024
Acute Medicine, Royal Stoke University Hospital, Stoke-on-Trent, GBR.
Although parenteral iron is widely used to treat iron deficiency anemia (IDA), some side effects have been inadequately explored. Hypophosphatemia is becoming a well-documented, yet poorly understood, side effect of parenteral iron infusion, oftentimes causing serious and/or prolonged complications. In this article, we discuss the case of a 33-year-old female with IDA who suffered debilitating physical and mental symptoms of significant recurrent hypophosphatemia following a single standard dose of parenteral iron administration.
View Article and Find Full Text PDFJ Clin Med
November 2024
Division of Nephrology, Department of Medicine, Showa University School of Medicine, Tokyo 142-8666, Japan.
Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor approved to treat anemia of chronic kidney disease (CKD). The efficacy and safety of roxadustat compared with parenteral erythropoiesis-stimulating agents (ESAs) were evaluated in patients with anemia of CKD receiving peritoneal dialysis (PD). This analysis pooled data from four phase 3, multicenter, randomized, open-label, active-comparator studies (PYRENEES, SIERRAS, HIMALAYAS, ROCKIES).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!